Roche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer from recurring after surgery, at the third attempt. The new draft guidance means that the HER2 inhibitor can be given as an a...
Original Article: Price cut unlocks NICE nod for Perjeta in post-surgery breast cancer